The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
Join Julius Clinical at Alzheimer's Association International Conference in London from July 12-15, 2026. Meet our neuroscience experts at AAIC to discover how Julius Clinical supports efficient, high-quality clinical trials across complex neurol...
The GRIPonMASH consortium has reached a significant milestone in screening individuals at risk of metabolic dysfunction-associated steatotic liver disease (MASLD). Julius Clinical is proud to contribute to this achievement.The GRIPonMASH conso...
The Netherlands, 09 February 2026Ubiquitous in real-world data (RWD) projects, Electronic Medical Record (EMR) and Electronic Health Record (EHR) data is making its way slowly but surely into clinical trials, and the possibilities appear endle...
"*" indicates required fields
"*" indicates required fields
P95 and Julius Clinical have merged to form a leading global, full-service clinical research organization (CRO) with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. Read more here.
